Lymphomas | Clinical

May 06, 2021

The National Comprehensive Cancer Network has added loncastuximab tesirine-lpyl to the NCCN Clinical Practice Guidelines in oncology for B-cell lymphomas.

May 04, 2021

The relapse-free survival benefit observed with rituximab maintenance added to autologous stem cell transplant suggests that the treatment strategy may help with disease eradication.

April 30, 2021

Here is a look back at the FDA happenings from the month of April 2021.

April 25, 2021

In an interview with Targeted Oncology, Scott R. Solomon, MD, a medical oncologist with the Blood and Marrow Transplant Program, Leukemia and Cellular Immunotherapy Program at the Northside Hospital Cancer Institute, discussed the efficacy of liso-cel in large B-cell lymphoma patients with prior anti-CD19 exposure and future research.

April 23, 2021

The FDA has granted approval top loncastuximab tesirine for the treatment of relapsed or refractory diffuse large B-cell lymphoma, according to a press release from ADC Therapeutics.

April 23, 2021

When given at the recommended phase 2 dose, lenzilumab in combination with taxicabtagene ciloleucel, induced a 100% objective response rate while showing no severe cytokine release syndrome cases or severe neurotoxicity in patients with relapsed or refractory diffuse large B-cell lymphoma.

April 22, 2021

Citing clinical pearls from her own experience in working with patients with relapsed/refractory follicular lymphoma, Kami Maddocks, MD, gives advice to colleagues in their efforts to combat follicular lymphoma.

April 22, 2021

Kami Maddocks, MD, lists the future directions and unmet needs present in treating relapsed/refractory follicular lymphoma.

April 22, 2021

The challenges faced in treating patients beyond second-line treatment are addressed. Kami Maddocks, MD, reviews the frequency of patients who require third- and fourth-line treatment, in addition to the factors that affect treatment decisions in later lines of therapy.

April 22, 2021

Considerations for subsequent treatment options in the second-line setting for patients with follicular lymphoma are reviewed by an expert hematologist.